Sanofi: CEO Leaves With Project Rejuvenation Unfinished, But Stock Undervalued
Source: SeekingAlpha
2026-02-12 16:45:15 ET
Investment Overview
Sanofi ( SNY ), native ticker Euronext Paris: SAN, reported its Q4 and full-year earnings on January 29th, announcing net sales up >9.9% year-on-year, to €43.6bn in 2025, and net income up >12%, to €9.6bn....
Read the full article on Seeking Alpha
For further details see:
Sanofi: CEO Leaves With Project Rejuvenation Unfinished, But Stock Undervalued
Sanofi
NASDAQ: SNY
SNY Trading
-0.56% G/L:
$44.155 Last:
1,077,036 Volume:
$44.07 Open:
SNY Latest News
February 23, 2026 01:42:29 pm
Kraig Biocraft Laboratories Featured on the Cover of National Geographic
February 18, 2026 08:45:56 am
It's Not Synthetic, It's Real. Kraig Labs Nears Spider Silk Breakthrough
SNY Stock Data
$119,804,457,217
2,430,957,423
N/A
389
N/A
Pharmaceuticals
Healthcare
FR
Paris
